Profound Medical Corp
PROF
Get informed when a big investor buys or sells
+ FollowMarket Cap$240.92M
Close$
$-4.77
172.8% downside
Current Fair Value
172.8% downsideOvervalued by 172.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $240.92 Million |
|---|---|
| Enterprise Value | $207.68 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.43 |
| Beta | 0.53 |
| Outstanding Shares | 36,350,665 |
Return
| Return on Equity | 164.32% |
|---|---|
| Return on Assets | 131.19% |
| Return on Invested Capital | -49.88% |
Valuation & Multiples
| P/E Ratio | -6.84 |
|---|---|
| PEG | 17.43 |
| Price to Sales | - |
| Price to Book Ratio | 6.55 |
| Enterprise Value to Revenue | 24.38 |
| Enterprise Value to EBIT | -7.82 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.22
Average shareholder expectationRevenue Estimate
$4.75 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.23
Average shareholder expectationRevenue Estimate
$6.33 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.9096▲ 190.96% |
|---|---|
| Total Calls | 33,200▲ Infinity% |
| Total Puts | 63,400▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 45.01%▼ 7.25% |
|---|---|
| Total Invested | $105.59M▼ 16.40% |
| Investors Holding | 61▼ 2.00% |
ESG Score
No data
About Profound Medical Corp
Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. Profound is commercializing TULSA-PRO®, a technology that combines real-time MR...